• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞通透的 G7-18NATE 构建体进入细胞并与 Grb-7-SH2 结构域结合。

Uptake of a cell permeable G7-18NATE contruct into cells and binding with the Grb-7-SH2 domain.

机构信息

Department of Biochemistry and Molecular Biology, Monash University, VIC 3800, Australia.

出版信息

Biopolymers. 2011;96(2):181-8. doi: 10.1002/bip.21403.

DOI:10.1002/bip.21403
PMID:20564009
Abstract

Grb7 is an adapter protein found to be overexpressed in several breast and other cancer cell types along with ErbB2. Grb7 is normally an interaction partner with focal adhesion kinase and in cancer cells also aberrantly interacts with ErbB2. It is thus implicated in the migratory and proliferative potential of cancer cells. Previous studies have shown that the phage display-derived cyclic nonphosphorylated inhibitor peptide, G7-18NATE, when linked to Penetratin, is able to interfere with the interaction of Grb7 with its upstream binding partners and to impact on both cell migration and proliferation. Here we report the synthesis of a biotinylated G7-18NATE covalently attached to just the last seven residues of Penetratin (G7-18NATE-P-Biotin). We demonstrate that this construct is taken up efficiently into MDA-MB-468 breast cancer cells and colocalizes with Grb7 in the cytoplasm. We also used isothermal titration calorimetry to determine the binding affinity of G7-18NATE-P-Biotin to the Grb7-SH2 domain, and showed that it binds with micromolar affinity (K(d) = 14.4 microM), similar to the affinity of G7-18NATE (K(d) = 35.4 microM). Together this shows that this shorter G7-18NATE-P-Biotin construct is suitable for further studies of the antiproliferative and antimigratory potential of this inhibitor.

摘要

Grb7 是一种在多种乳腺癌和其他癌细胞类型中过表达的衔接蛋白,同时伴随着 ErbB2 的过表达。Grb7 通常是粘着斑激酶的相互作用伙伴,在癌细胞中也异常地与 ErbB2 相互作用。因此,它与癌细胞的迁移和增殖潜力有关。先前的研究表明,噬菌体展示衍生的非磷酸化环状抑制剂肽 G7-18NATE,与 Penetratin 连接后,能够干扰 Grb7 与其上游结合伙伴的相互作用,并影响细胞迁移和增殖。在这里,我们报告了一种生物素化的 G7-18NATE 与 Penetratin 的最后七个残基共价连接的合成(G7-18NATE-P-Biotin)。我们证明了这种构建体能够有效地被 MDA-MB-468 乳腺癌细胞摄取,并与细胞质中的 Grb7 共定位。我们还使用等温滴定量热法测定了 G7-18NATE-P-Biotin 与 Grb7-SH2 结构域的结合亲和力,结果表明它以微摩尔亲和力(Kd = 14.4 microM)结合,与 G7-18NATE 的亲和力相似(Kd = 35.4 microM)。这表明这个较短的 G7-18NATE-P-Biotin 构建体适合进一步研究这种抑制剂的抗增殖和抗迁移潜力。

相似文献

1
Uptake of a cell permeable G7-18NATE contruct into cells and binding with the Grb-7-SH2 domain.细胞通透的 G7-18NATE 构建体进入细胞并与 Grb-7-SH2 结构域结合。
Biopolymers. 2011;96(2):181-8. doi: 10.1002/bip.21403.
2
Interaction of the non-phosphorylated peptide G7-18NATE with Grb7-SH2 domain requires phosphate for enhanced affinity and specificity.非磷酸化肽 G7-18NATE 与 Grb7-SH2 结构域的相互作用需要磷酸基团来增强亲和力和特异性。
J Mol Recognit. 2012 Jan;25(1):57-67. doi: 10.1002/jmr.2148.
3
Structural basis of binding by cyclic nonphosphorylated peptide antagonists of Grb7 implicated in breast cancer progression.环状非磷酸化肽拮抗剂与 Grb7 结合的结构基础,Grb7 与乳腺癌的进展有关。
J Mol Biol. 2011 Sep 23;412(3):397-411. doi: 10.1016/j.jmb.2011.07.030. Epub 2011 Jul 23.
4
NMR analysis of G7-18NATE, a nonphosphorylated cyclic peptide inhibitor of the Grb7 adapter protein.Grb7衔接蛋白的非磷酸化环肽抑制剂G7-18NATE的核磁共振分析。
Biopolymers. 2007;88(2):174-81. doi: 10.1002/bip.20667.
5
Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation.Grb7的SH2结构域及其与癌细胞迁移和增殖环肽抑制剂的相互作用。
BMC Struct Biol. 2007 Sep 25;7:58. doi: 10.1186/1472-6807-7-58.
6
Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.Grb7 肽与阿霉素或曲妥珠单抗(赫赛汀)联合治疗可协同抑制乳腺癌细胞的生长。
Br J Cancer. 2007 May 21;96(10):1520-5. doi: 10.1038/sj.bjc.6603732. Epub 2007 Apr 10.
7
Preparation and crystallization of the Grb7 SH2 domain in complex with the G7-18NATE nonphosphorylated cyclic inhibitor peptide.与G7-18NATE非磷酸化环抑制剂肽复合的Grb7 SH2结构域的制备与结晶。
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Dec 1;66(Pt 12):1640-3. doi: 10.1107/S1744309110041850. Epub 2010 Nov 26.
8
Evaluation of Cyclic Peptide Inhibitors of the Grb7 Breast Cancer Target: Small Change in Cargo Results in Large Change in Cellular Activity.评估 Grb7 乳腺癌靶标的环状肽抑制剂:货物的微小变化导致细胞活性的巨大变化。
Molecules. 2019 Oct 17;24(20):3739. doi: 10.3390/molecules24203739.
9
Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis.用于Grb7信号转导蛋白和胰腺癌转移的特异性肽配体。
J Natl Cancer Inst. 2006 Apr 5;98(7):491-8. doi: 10.1093/jnci/djj105.
10
Cyclic Peptides Incorporating Phosphotyrosine Mimetics as Potent and Specific Inhibitors of the Grb7 Breast Cancer Target.含有磷酸酪氨酸模拟物的环肽作为Grb7乳腺癌靶点的强效特异性抑制剂
J Med Chem. 2015 Oct 8;58(19):7707-18. doi: 10.1021/acs.jmedchem.5b00609. Epub 2015 Sep 23.

引用本文的文献

1
Peptide-Based Strategies for Targeted Tumor Treatment and Imaging.基于肽的靶向肿瘤治疗与成像策略
Pharmaceutics. 2021 Apr 2;13(4):481. doi: 10.3390/pharmaceutics13040481.
2
Phosphotyrosine isosteres: past, present and future.磷酸酪氨酸类似物:过去、现在和未来。
Org Biomol Chem. 2020 Jan 28;18(4):583-605. doi: 10.1039/c9ob01998g. Epub 2019 Nov 28.
3
Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target.Grb7,EGFR/ErbB 信号通路的关键介质,在癌症发生发展过程中的作用及作为潜在治疗靶点。
Cells. 2019 May 10;8(5):435. doi: 10.3390/cells8050435.
4
Shortened Penetratin Cell-Penetrating Peptide Is Insufficient for Cytosolic Delivery of a Grb7 Targeting Peptide.缩短的穿膜肽不足以实现Grb7靶向肽的胞质递送。
ACS Omega. 2017 Feb 28;2(2):670-677. doi: 10.1021/acsomega.6b00561. Epub 2017 Feb 23.
5
Insight into the Selectivity of the G7-18NATE Inhibitor Peptide for the Grb7-SH2 Domain Target.深入了解G7-18NATE抑制剂肽对Grb7-SH2结构域靶点的选择性。
Front Mol Biosci. 2017 Sep 26;4:64. doi: 10.3389/fmolb.2017.00064. eCollection 2017.
6
Targeting SH2 domains in breast cancer.靶向乳腺癌中的SH2结构域。
Future Med Chem. 2014;6(17):1909-26. doi: 10.4155/fmc.14.120.